Hye Sung Kim, Internal Medicine Resident Physician at Temple Health, shared a post on LinkedIn:
“The DART study just hit the ASCO 2026 oral abstract stage, presented by Dr. Sandip Patel! Remarkable accrual across rare and ultra-rare solid tumors, with translational biomarker analysis ongoing to guide next steps.
Toxicity is real (22% G3-4 TRAEs), but the science ahead is exciting. Endlessly grateful to my mentor Dr. Young Kwang Chae and the DART team for bringing me into this work and showing me what practice-changing early phase trials look like from the inside.”
Title: A Phase II Basket Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART SWOG 1609) in Patients with Nonpancreatic Neuroendocrine Tumors
Authors: Sandip P Patel, Megan Othus, Young Kwang Chae, Francis J Giles, Donna E Hansel, Preet Paul Singh, Annette Fontaine, Manisha H Shah, Anup Kasi, Tareq Al Baghdadi, Marc Matrana, Zoran Gatalica, W Michael Korn, Jourdain Hayward, Christine McLeod, Helen X Chen, Elad Sharon, Edward Mayerson, Christopher W Ryan, Melissa Plets, Charles D Blanke, Razelle Kurzrock
Other articles featuring Hye Sung Kim on OncoDaily.